Financial Contrast: Achaogen (OTCMKTS:AKAOQ) vs. Lucy Scientific Discovery (NASDAQ:LSDI)

Lucy Scientific Discovery (NASDAQ:LSDI) and Achaogen (OTCMKTS:AKAOQ) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, valuation and risk.

Valuation & Earnings

This table compares Lucy Scientific Discovery and Achaogen’s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lucy Scientific Discovery	$16,732.00	54.21	-$8.99 million	($7.00)	-0.07
Achaogen	$8.73 million	0.14	-$186.51 million	N/A	N/A

Lucy Scientific Discovery has higher earnings, but lower revenue than Achaogen.

Insider & Institutional Ownership

72.6% of Lucy Scientific Discovery shares are held by institutional investors. 7.8% of Achaogen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

Lucy Scientific Discovery has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500. Comparatively, Achaogen has a beta of -0.81, meaning that its stock price is 181% less volatile than the S&P 500.

Profitability

This table compares Lucy Scientific Discovery and Achaogen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lucy Scientific Discovery	N/A	-294.74%	-137.65%
Achaogen	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Lucy Scientific Discovery and Achaogen, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lucy Scientific Discovery	0	0	0	0	N/A
Achaogen	0	0	0	0	N/A

About Lucy Scientific Discovery

Lucy Scientific Discovery Inc., an early stage psychotropics contract manufacturing company, engaged in the research, manufacturing, and commercialization of psychedelic products. The company offers biological raw materials, active pharmaceutical ingredients (APIs), and finished biopharmaceutical products. It also develops and produces highly controlled agricultural grow environments for plant manufacturing and replication applications. The company was formerly known as Hollyweed North Cannabis Inc. and changed its name to Lucy Scientific Discovery Inc. in May 2021. Lucy Scientific Discovery Inc. was incorporated in 2017 and is headquartered in Victoria, Canada.

About Achaogen

Achaogen, Inc., a biopharmaceutical company, focuses on the development and commercialization of antibacterial agents for multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae. It is also involved in the development of antibacterial candidate C-Scape, an orally-administered combination of clavulanate and ceftibuten, which targets serious bacterial infections due to expanded spectrum beta-lactamases producing enterobacteriaceae. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to support plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California. On April 15, 2019, Achaogen, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on May 29, 2020.